web analytics

AI Robotics Tech; the Story of GBT Technologies Inc (OTCMKTS: GTCH)

0

GBT Technologies Inc (OTCMKTS: GTCH) has been on the move in recent days off its .02 base to recent highs of $0.10. The stock is trading significant volume and quickly attracting legions of new shareholders. On Thursday dollar volume easily topped $5 million.

The Company just announced it is researching AI based, robotics technology for the medial field. Due to the expected growth in the global medical robotics industry through 2023*, a wide range of robots are being developed to serve in a variety of roles within the medical environment. Probably one of the most famous medicals robot is the da Vinci Surgical System**, that was approved by the FDA in 2000. This system is designed to perform minimally invasive surgeries and is controlled by a surgeon from a console.

GBT Technologies Inc (OTCMKTS: GTCH) is a development-stage company that considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI)-enabled mobile technology platforms.  GBT has a portfolio of Intellectual Property that when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software.  GBT’s system envisions the creation of a global mesh network.  The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

The Company is seeking approval filing for its qTerm device with the United States Food and Drug Administration (“FDA”). The qTerm, a human vitals device powered by AI, is aimed to measure human vitals with a touch of a finger. The web application, when developed, will enable a direct internet access to the user’s data anywhere around the world including his/hers geo-location, statistical and personal information. Upon user’s permission, synchronized with the mobile app, the body temperature and geographical location will be anonymously shared with other users to provide health risk proximity alerts. GBT’s AI will perform on-going vitals monitoring and analytics to provide personal health related alerts in case results are of a concern. Upon taking vitals measurement, the web server application is designed to present the data, with full synchronization with the mobile app, in real time including color code for body temperature status (Green, Yellow, Red). The web application is also planned to include additional health related important information like location of close clinics, urgent care sites and hospitals. The web application is targeted to be completed by mid-2021.

GBT is also developing a web server application for GBT Tokenize Corp’s qTerm device. The web server, when developed, will be synchronized with qTerm’s mobile application. The web interface when developed will show user’s location, temperature and other health related information. The web server is designed with the goal of user’s privacy and confidentiality to be secured via personal account setup system and industry standard web oriented security mechanisms.

To Find out the inside Scoop on GTCH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GTCHOn January 21 GTCH announced it is researching AI based, robotics technology for the medial field. Due to the expected growth in the global medical robotics industry through 2023*, a wide range of robots are being developed to serve in a variety of roles within the medical environment. Probably one of the most famous medicals robot is the da Vinci Surgical System**, that was approved by the FDA in 2000. This system is designed to perform minimally invasive surgeries and is controlled by a surgeon from a console.

GBT is commencing new research that is targeting medical application robotics, empowered by its AI system. In this research, the Company will focus on the innovation and technological advancements that is offered by AI to enable medical robots achieving higher standards. Using AI technology, robots can perform minimally invasive procedures with high accuracy and precision. For example, performing laser incisions on soft tissue, especially for microsurgeries. Using expert system guidance, one of the research goals, is to perform robotic based laser incisions simulation based on surgeon high level commands where an AI engine controls a high precision laser beam to achieve a desired incision shape, length, and depth. Another planned topic to be researched is robotic assistance for biopsies where under robotic guidance a surgeon can performs a biopsy based on 3D imaging of the area. The Company plans to develop simulated procedures and flows to be tested for further medical purposes.

CTO Danny Rittman stated: “The field of robotics is under constant development in many areas of our daily lives. One of the popular fields that robotics researchers invest major efforts, is the medical arena. Today’s robots can take patient’s vitals, assist with prosthetics, perform an endoscopy (looking inside the human body typically via Camera) and complex surgeries. As the demand for less invasive, less painful, high precision procedures is rapidly growing, we will be evaluating our AI system for these types of procedure. Our goal is to utilize a high precision mechanical arm based robotic system in simulated medical procedures supervised by an expert system. The plan is to investigate into soft tissues ultra-fine laser incisions, 3D imaging, and intelligent navigation to organs sites of interest. Our goal is to develop low and high level programs to command robotic mechanism for various physicians assisting tasks. Our research will involve full robotic automation, a physician assistant, and a combination of both. The research is planned to be on-going and we plan to produce technical papers with conclusions and results. Based on our results, we will then seek commercial partners in this domain.”

For More on GTCH Subscribe Right Now

GTCH has been on the move in recent days off its .02 base to recent highs of $0.10. The stock is trading significant volume and quickly attracting legions of new shareholders. On Thursday dollar volume easily topped $5 million. The Company just announced it is researching AI based, robotics technology for the medial field. Due to the expected growth in the global medical robotics industry through 2023*, a wide range of robots are being developed to serve in a variety of roles within the medical environment. Probably one of the most famous medicals robot is the da Vinci Surgical System**, that was approved by the FDA in 2000. This system is designed to perform minimally invasive surgeries and is controlled by a surgeon from a console. GBT is seeking approval filing for its qTerm device with the United States Food and Drug Administration. The qTerm, a human vitals device powered by AI, is aimed to measure human vitals with a touch of a finger. The web application, when developed, will enable a direct internet access to the user’s data anywhere around the world including his/hers geo-location, statistical and personal information. We will be updating on GTCH when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GTCH.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in GTCH either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.